유방촬영술 시장 : 시장 규모 및 점유율 산업 분석(서비스별, 영상 진단법별, 최종사용자별, 지역별), 전망 및 예측(2026-2033년)

The Global Mammography Market is expected to reach USD 10.0 billion by 2033, growing at a CAGR of 5.3% during (2026 - 2033).

Rising breast cancer incidence, expanding screening programs, early detection awareness, and demand for accurate, low-radiation, patient-friendly imaging solutions are driving the Mammography Market across hospitals, diagnostic imaging centers, specialty clinics, mobile screening units, and community healthcare facilities. Growth is further strengthened by digital mammography, 3D breast tomosynthesis, AI-assisted image analysis, computer-aided detection, cloud-enabled image management, and integrated breast imaging workflows.

Key Market Trends & Insights

• By service, Screening dominated the market in 2025 with USD 4.1 billion and is projected to reach USD 5.9 billion by 2033, growing at a CAGR of 4.8% during (2026 - 2033).
• Interventional is expected to grow fastest by service, registering a CAGR of 6.5% during (2026 - 2033), supported by image-guided biopsy, lesion localization, and minimally invasive breast tissue evaluation.
• By imaging modality, 2D Digital dominated the market in 2025 with USD 2.9 billion and is projected to reach USD 4.1 billion by 2033, growing at a CAGR of 4.7% during (2026 - 2033).
• 3D Digital Breast Tomosynthesis is projected to reach USD 4.0 billion by 2033, growing at a CAGR of 5.4% during (2026 - 2033), supported by improved visualization of overlapping breast tissue and stronger adoption in advanced screening workflows.
• Contrast-enhanced mammography is projected to reach USD 1.1 billion by 2033, growing at a CAGR of 6.3% during (2026 - 2033), driven by lesion characterization, tumor vascularity assessment, and use as a complementary diagnostic tool.
• By end-user, Hospitals dominated the market in 2025 with USD 3.0 billion and is projected to reach USD 4.3 billion by 2033, growing at a CAGR of 4.7% during (2026 - 2033).
• Diagnostic Centers is expected to grow fastest by end-user, registering a CAGR of 5.9% during (2026 - 2033), supported by outpatient imaging demand, convenient diagnostic access, and expansion of standalone breast imaging services.
• Regionally, North America dominated the market in 2025 with USD 2.5 billion and is projected to reach USD 3.6 billion by 2033, while LAMEA is expected to grow fastest with a CAGR of 7.3% during (2026 - 2033).

Rising emphasis on early breast cancer detection is expanding demand for mammography systems across preventive screening, diagnostic evaluation, and image-guided intervention. Healthcare providers are investing in digital platforms, 3D tomosynthesis, contrast-enhanced mammography, AI-assisted interpretation, and remote image-sharing solutions to improve diagnostic accuracy and workflow efficiency. The market is also benefiting from patient-centered care models focused on comfort, lower radiation exposure, faster reporting, and improved screening adherence. Emerging economies are creating additional growth potential through healthcare infrastructure expansion, portable systems, mobile mammography units, and wider screening access.

The competitive environment is moderately consolidated and innovation-driven, with multinational imaging companies and specialized breast imaging manufacturers competing on image quality, detector performance, AI integration, workflow efficiency, patient comfort, biopsy capability, and service support. Hologic holds a strong leadership position through its breast health portfolio, while GE HealthCare and Siemens Healthineers compete through advanced digital mammography, tomosynthesis, contrast-enhanced mammography, biopsy guidance, and enterprise imaging capabilities. Fujifilm, Planmed, IMS Giotto, Metaltronica, Trivitron, Allengers, and MEDI-FUTURE strengthen the market through regional reach, specialized platforms, value-oriented systems, and dedicated mammography portfolios.

Drivers

• Integration of Advanced Artificial Intelligence in Mammography Screening
• Rising Demand for Contrast-Enhanced Mammography as a Complementary Diagnostic Tool
• Increasing Emphasis on Early Breast Cancer Detection and Screening Programs
• Technological Innovations and Market Expansion in Emerging Economies

Restraints

• Regulatory Uncertainty Surrounding Artificial Intelligence Integration
• High Cost and Limited Reimbursement Frameworks
• Socioeconomic and Cultural Barriers to Screening Uptake

Opportunities

• Integration of Artificial Intelligence for Enhanced Mammography Diagnostics
• Expansion of 3D Mammography and Digital Breast Tomosynthesis Technologies
• Development of Patient-Centric Education and Engagement Platforms in Mammography Services

Challenges

• Regulatory Ambiguity and Compliance Challenges in Mammography AI Integration
• Technological and Workflow Inefficiencies in Transitioning to 3D Mammography
• Data Privacy Concerns and Interoperability Barriers in Mammography Information Systems

Market Share Analysis

The global Mammography Market is moderately consolidated and technology-driven, led by established medical imaging companies, dedicated breast imaging specialists, and regional diagnostic equipment manufacturers. Hologic leads through its comprehensive breast health portfolio and strong position in digital breast tomosynthesis, while GE HealthCare and Siemens Healthineers maintain strong positions through advanced mammography platforms, biopsy guidance, workflow tools, and global imaging service networks. Fujifilm, Planmed, IMS Giotto, Metaltronica, Trivitron, Allengers, and MEDI-FUTURE add competitive depth through detector expertise, dedicated mammography platforms, regional manufacturing, cost-effective systems, and specialized breast imaging portfolios.

Service Outlook

Based on Service, the market is segmented into Screening, Diagnostic, and Interventional. The Screening market dominated the Global Mammography Market by Service in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 5.9 billion by 2033, growing at a CAGR of 4.8 % during the forecast period. The Diagnostic market is expected to witness a CAGR of 5.7% during (2026 - 2033). The Interventional market is expected to witness a CAGR of 6.5% during (2026 - 2033).

Screening remains the core service category as healthcare systems focus on early breast cancer detection, population-based screening programs, and routine imaging for asymptomatic women. Diagnostic mammography supports follow-up evaluation of abnormal screening results, symptomatic cases, and suspicious clinical findings requiring more detailed imaging. Interventional mammography supports image-guided biopsy, lesion localization, and minimally invasive tissue evaluation. These services collectively support the full breast cancer care pathway from early detection to diagnostic confirmation and treatment planning.

Imaging Modality Outlook

Based on Imaging Modality, the market is segmented into 2D Digital, 3D Digital Breast Tomosynthesis, Contrast-enhanced, and Other Imaging Modality. The 2D Digital market dominated the Global Mammography Market by Imaging Modality in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 4.1 billion by 2033, growing at a CAGR of 4.7 % during the forecast period. The 3D Digital Breast Tomosynthesis market is expected to witness a CAGR of 5.4% during (2026 - 2033). Additionally, The Contrast-enhanced market is expected to witness highest CAGR of 6.3% during (2026 - 2033).

2D Digital remains widely adopted due to its established clinical role, broad availability, efficient image acquisition, and suitability for routine screening workflows. 3D Digital Breast Tomosynthesis is gaining strong relevance as it improves visualization of overlapping breast tissue and supports more accurate lesion detection, especially in dense breast cases. Contrast-enhanced mammography supports evaluation of suspicious lesions and tumor vascularity, serving as a useful diagnostic adjunct. Other Imaging Modality includes complementary and emerging breast imaging techniques used selectively in advanced diagnostic workflows.

End-User Outlook

Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers, and Other End-User. The Hospitals market dominated the Global Mammography Market by End-User in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 4.3 billion by 2033, growing at a CAGR of 4.7 % during the forecast period. The Specialty Clinics market is expected to witness a CAGR of 5.5% during (2026 - 2033). Additionally, The Diagnostic Centers market is expected to witness highest CAGR of 5.9% during (2026 - 2033).

Hospitals remain the leading end-user group because they combine high patient volume, radiology infrastructure, oncology services, interventional capabilities, and multidisciplinary breast care pathways. Specialty Clinics support targeted breast health services with focused screening, diagnosis, and patient-centered workflows. Diagnostic Centers are important for outpatient imaging access, routine screening, and faster diagnostic availability. Other End-User includes mobile screening units, community healthcare facilities, and specialized settings that help expand mammography access among underserved and remote populations.

Regional Outlook

Region-wise, the Mammography Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America market dominated the Global Mammography Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 3.6 billion by 2033, growing at a CAGR of 4.7 % during the forecast period. The Europe market is expected to witness a CAGR of 4.9% during (2026 - 2033). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.8% during (2026 - 2033).

North America remains the leading regional market, supported by established breast cancer screening practices, advanced healthcare infrastructure, reimbursement coverage, and adoption of digital breast tomosynthesis and AI-enabled imaging. Europe benefits from organized screening programs, modernization of diagnostic imaging infrastructure, and continued emphasis on early breast cancer detection. Asia Pacific is expanding through healthcare infrastructure development, increasing screening awareness, rising diagnostic investments, and improving access to advanced imaging systems. LAMEA is developing steadily as breast cancer screening access improves, digital mammography adoption increases, and healthcare infrastructure gradually strengthens.

Recent Strategies Deployed in the Market

• GE HealthCare and RadNet's DeepHealth expanded their AI-enabled mammography collaboration internationally around the Senographe Pristina platform, Pristina Via, and DeepHealth's cloud-based Breast Suite.
• 2025-May: RamSoft integrated Therapixel's MammoScreen AI into its PowerServer and OmegaAI platforms, enabling AI-supported 2D and 3D mammography workflow capabilities within existing PACS environments.
• 2025-March: iCAD and RamSoft entered a strategic commercial and integration partnership to expand ProFound AI Breast Health Suite across North America through RamSoft's cloud-based PowerServer RIS/PACS platform.
• 2024-November: GE HealthCare and RadNet's DeepHealth partnered to integrate SmartMammo with GE HealthCare's Senographe Pristina mammography system, combining hardware, cloud-native workflow, and AI-enabled breast screening tools.
• 2024-July: Hologic acquired Endomagnetics to expand its broader breast health technology portfolio and strengthen its position across screening, diagnosis, and intervention pathways.
• 2024-April: iCAD and Densitas partnered to combine ProFound Breast Health Suite with AI technologies for mammography quality, breast density analysis, operational management, detection, and risk assessment.

List of Key Companies Profiled

• Hologic, Inc.
• GE HealthCare Technologies Inc.
• Siemens Healthineers AG
• FUJIFILM Holdings Corporation
• Planmed Oy
• IMS Giotto S.p.A.
• Metaltronica S.p.A.
• Trivitron Healthcare Pvt. Ltd.
• Allengers Medical Systems Ltd.
• MEDI-FUTURE Co., Ltd.

Global Mammography Market Report Segmentation

By Service

• Screening
• Diagnostic
• Interventional

By Imaging Modality

• 2D Digital
• 3D Digital Breast Tomosynthesis
• Contrast-enhanced
• Other Imaging Modality

By End-User

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Other End-User

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology

• 1.1 Market Definition
• 1.2 Analysis Period & Currency
• 1.3 Segmentation
• 1.4 Mammography Market, by Geography
• 1.5 Research Methodology

Chapter 2. Market Overview

• 2.1 COVID-19 Impact
• 2.2 Market Composition and Scenario

Chapter 3. Key Factors Impacting Market

• 3.1 Market Drivers
• 3.2 Market Restraints
• 3.3 Market Opportunities
• 3.4 Market Challenges
• 3.5 Market Trends
• 3.6 State of Competition
• 3.7 Market Consolidation
• 3.8 Key Customer Criteria

Chapter 4. Product Life Cycle

Chapter 5. Value Chain Analysis of Mammography Market

Chapter 6. Competition Analysis - Global

• 6.1 Market Share Analysis
• 6.2 Recent Developments
  • 6.2.1 Mergers & Acquisitions
  • 6.2.2 Product Launch & Product Expansion
  • 6.2.3 Partnership, Collaboration & Agreements
  • 6.2.4 Geographical Expansion

Chapter 7. Segmentation By Service

• 7.1 Screening
• 7.2 Diagnostic
• 7.3 Interventional

Chapter 8. Segmentation By Imaging Modality

• 8.1 D Digital
• 8.2 D Digital Breast Tomosynthesis
• 8.3 Contrast-Enhanced
• 8.4 Other Imaging Modalities

Chapter 9. Segmentation By End-User

• 9.1 Hospitals
• 9.2 Specialty Clinics
• 9.3 Diagnostic Centers
• 9.4 Other End-User

Chapter 10. North America Market

• 10.1 Market Overview
• 10.2 Key Factors Impacting Market
  • 10.2.1 Market Drivers
  • 10.2.2 Market Restraints
  • 10.2.3 Market Opportunities
  • 10.2.4 Market Challenges
  • 10.2.5 Market Trends
  • 10.2.6 State of Competition
  • 10.2.7 Market Consolidation
  • 10.2.8 Key Customer Criteria
• 10.3 Product Life Cycle
• 10.4 Segmentation By Service
  • 10.4.1 Screening
  • 10.4.2 Diagnostic
  • 10.4.3 Interventional
• 10.5 Segmentation By Imaging Modality
  • 10.5.1 D Digital
  • 10.5.2 D Digital Breast Tomosynthesis
  • 10.5.3 Contrast-enhanced
  • 10.5.4 Other Imaging Modality
• 10.6 Segmentation By End-User
  • 10.6.1 Hospitals
  • 10.6.2 Specialty Clinics
  • 10.6.3 Diagnostic Centers
  • 10.6.4 Other End-User
• 10.7 Segmentation By Country
  • 10.7.1 US
    • 10.7.1.1 Segmentation By Service
      • 10.7.1.1.1 Screening
      • 10.7.1.1.2 Diagnostic
      • 10.7.1.1.3 Interventional
    • 10.7.1.2 Segmentation By Imaging Modality
      • 10.7.1.2.1 D Digital
      • 10.7.1.2.2 D Digital Breast Tomosynthesis
      • 10.7.1.2.3 Contrast-Enhanced
      • 10.7.1.2.4 Other Imaging Modality
    • 10.7.1.3 Segmentation By End-User
      • 10.7.1.3.1 Hospitals
      • 10.7.1.3.2 Specialty Clinics
      • 10.7.1.3.3 Diagnostic Centers
      • 10.7.1.3.4 Other End-User
  • 10.7.2 Canada
    • 10.7.2.1 Segmentation By Service
      • 10.7.2.1.1 Screening
      • 10.7.2.1.2 Diagnostic
      • 10.7.2.1.3 Interventional
    • 10.7.2.2 Segmentation By Imaging Modality
      • 10.7.2.2.1 D Digital
      • 10.7.2.2.2 D Digital Breast Tomosynthesis
      • 10.7.2.2.3 Contrast-Enhanced
      • 10.7.2.2.4 Other Imaging Modality
    • 10.7.2.3 Segmentation By End-User
      • 10.7.2.3.1 Hospitals
      • 10.7.2.3.2 Specialty Clinics
      • 10.7.2.3.3 Diagnostic Centers
      • 10.7.2.3.4 Other End-User
  • 10.7.3 Mexico
    • 10.7.3.1 Segmentation By Service
      • 10.7.3.1.1 Screening
      • 10.7.3.1.2 Diagnostic
      • 10.7.3.1.3 Interventional
    • 10.7.3.2 Segmentation By Imaging Modality
      • 10.7.3.2.1 D Digital
      • 10.7.3.2.2 D Digital Breast Tomosynthesis
      • 10.7.3.2.3 Contrast-Enhanced
      • 10.7.3.2.4 Other Imaging Modality
    • 10.7.3.3 Segmentation By End-User
      • 10.7.3.3.1 Hospitals
      • 10.7.3.3.2 Specialty Clinics
      • 10.7.3.3.3 Diagnostic Centers
      • 10.7.3.3.4 Other End-User
  • 10.7.4 Rest of North America
    • 10.7.4.1 Segmentation By Service
      • 10.7.4.1.1 Screening
      • 10.7.4.1.2 Diagnostic
      • 10.7.4.1.3 Interventional
    • 10.7.4.2 Segmentation By Imaging Modality
      • 10.7.4.2.1 D Digital
      • 10.7.4.2.2 D Digital Breast Tomosynthesis
      • 10.7.4.2.3 Contrast-Enhanced
      • 10.7.4.2.4 Other Imaging Modality
    • 10.7.4.3 Segmentation By End-User
      • 10.7.4.3.1 Hospitals
      • 10.7.4.3.2 Specialty Clinics
      • 10.7.4.3.3 Diagnostic Centers
      • 10.7.4.3.4 Other End-User

Chapter 11. Europe Market

• 11.1 Market Overview
• 11.2 Key Factors Impacting Market
  • 11.2.1 Market Drivers
  • 11.2.2 Market Restraints
  • 11.2.3 Market Opportunities
  • 11.2.4 Market Challenges
  • 11.2.5 Market Trends
  • 11.2.6 State of Competition
  • 11.2.7 Market Consolidation
  • 11.2.8 Key Customer Criteria
• 11.3 Product Life Cycle
• 11.4 Segmentation By Service
  • 11.4.1 Screening
  • 11.4.2 Diagnostic
  • 11.4.3 Interventional
• 11.5 Segmentation By Imaging Modality
  • 11.5.1 D Digital
  • 11.5.2 D Digital Breast Tomosynthesis
  • 11.5.3 Contrast-enhanced
  • 11.5.4 Other Imaging Modality
• 11.6 Segmentation By End-User
  • 11.6.1 Hospitals
  • 11.6.2 Specialty Clinics
  • 11.6.3 Diagnostic Centers
  • 11.6.4 Other End-User
• 11.7 Segmentation By Country
  • 11.7.1 Germany
    • 11.7.1.1 Segmentation By Service
      • 11.7.1.1.1 Screening
      • 11.7.1.1.2 Diagnostic
      • 11.7.1.1.3 Interventional
    • 11.7.1.2 Segmentation By Imaging Modality
      • 11.7.1.2.1 D Digital
      • 11.7.1.2.2 D Digital Breast Tomosynthesis
      • 11.7.1.2.3 Contrast-Enhanced
      • 11.7.1.2.4 Other Imaging Modality
    • 11.7.1.3 Segmentation By End-User
      • 11.7.1.3.1 Hospitals
      • 11.7.1.3.2 Specialty Clinics
      • 11.7.1.3.3 Diagnostic Centers
      • 11.7.1.3.4 Other End-User
  • 11.7.2 UK
    • 11.7.2.1 Segmentation By Service
      • 11.7.2.1.1 Screening
      • 11.7.2.1.2 Diagnostic
      • 11.7.2.1.3 Interventional
    • 11.7.2.2 Segmentation By Imaging Modality
      • 11.7.2.2.1 D Digital
      • 11.7.2.2.2 D Digital Breast Tomosynthesis
      • 11.7.2.2.3 Contrast-Enhanced
      • 11.7.2.2.4 Other Imaging Modality
    • 11.7.2.3 Segmentation By End-User
      • 11.7.2.3.1 Hospitals
      • 11.7.2.3.2 Specialty Clinics
      • 11.7.2.3.3 Diagnostic Centers
      • 11.7.2.3.4 Other End-User
  • 11.7.3 France
    • 11.7.3.1 Segmentation By Service
      • 11.7.3.1.1 Screening
      • 11.7.3.1.2 Diagnostic
      • 11.7.3.1.3 Interventional
    • 11.7.3.2 Segmentation By Imaging Modality
      • 11.7.3.2.1 D Digital
      • 11.7.3.2.2 D Digital Breast Tomosynthesis
      • 11.7.3.2.3 Contrast-Enhanced
      • 11.7.3.2.4 Other Imaging Modality
    • 11.7.3.3 Segmentation By End-User
      • 11.7.3.3.1 Hospitals
      • 11.7.3.3.2 Specialty Clinics
      • 11.7.3.3.3 Diagnostic Centers
      • 11.7.3.3.4 Other End-User
  • 11.7.4 Russia
    • 11.7.4.1 Segmentation By Service
      • 11.7.4.1.1 Screening
      • 11.7.4.1.2 Diagnostic
      • 11.7.4.1.3 Interventional
    • 11.7.4.2 Segmentation By Imaging Modality
      • 11.7.4.2.1 D Digital
      • 11.7.4.2.2 D Digital Breast Tomosynthesis
      • 11.7.4.2.3 Contrast-Enhanced
      • 11.7.4.2.4 Other Imaging Modality
    • 11.7.4.3 Segmentation By End-User
      • 11.7.4.3.1 Hospitals
      • 11.7.4.3.2 Specialty Clinics
      • 11.7.4.3.3 Diagnostic Centers
      • 11.7.4.3.4 Other End-User
  • 11.7.5 Spain
    • 11.7.5.1 Segmentation By Service
      • 11.7.5.1.1 Screening
      • 11.7.5.1.2 Diagnostic
      • 11.7.5.1.3 Interventional
    • 11.7.5.2 Segmentation By Imaging Modality
      • 11.7.5.2.1 D Digital
      • 11.7.5.2.2 D Digital Breast Tomosynthesis
      • 11.7.5.2.3 Contrast-Enhanced
      • 11.7.5.2.4 Other Imaging Modality
    • 11.7.5.3 Segmentation By End-User
      • 11.7.5.3.1 Hospitals
      • 11.7.5.3.2 Specialty Clinics
      • 11.7.5.3.3 Diagnostic Centers
      • 11.7.5.3.4 Other End-User
  • 11.7.6 Italy
    • 11.7.6.1 Segmentation By Service
      • 11.7.6.1.1 Screening
      • 11.7.6.1.2 Diagnostic
      • 11.7.6.1.3 Interventional
    • 11.7.6.2 Segmentation By Imaging Modality
      • 11.7.6.2.1 D Digital
      • 11.7.6.2.2 D Digital Breast Tomosynthesis
      • 11.7.6.2.3 Contrast-Enhanced
      • 11.7.6.2.4 Other Imaging Modality
    • 11.7.6.3 Segmentation By End-User
      • 11.7.6.3.1 Hospitals
      • 11.7.6.3.2 Specialty Clinics
      • 11.7.6.3.3 Diagnostic Centers
      • 11.7.6.3.4 Other End-User
  • 11.7.7 Rest of Europe
    • 11.7.7.1 Segmentation By Service
      • 11.7.7.1.1 Screening
      • 11.7.7.1.2 Diagnostic
      • 11.7.7.1.3 Interventional
    • 11.7.7.2 Segmentation By Imaging Modality
      • 11.7.7.2.1 D Digital
      • 11.7.7.2.2 D Digital Breast Tomosynthesis
      • 11.7.7.2.3 Contrast-Enhanced
      • 11.7.7.2.4 Other Imaging Modality
    • 11.7.7.3 Segmentation By End-User
      • 11.7.7.3.1 Hospitals
      • 11.7.7.3.2 Specialty Clinics
      • 11.7.7.3.3 Diagnostic Centers
      • 11.7.7.3.4 Other End-User

Chapter 12. Asia Pacific Market

• 12.1 Market Overview
• 12.2 Key Factors Impacting Market
  • 12.2.1 Market Drivers
  • 12.2.2 Market Restraints
  • 12.2.3 Market Opportunities
  • 12.2.4 Market Challenges
  • 12.2.5 Market Trends
  • 12.2.6 State of Competition
  • 12.2.7 Market Consolidation
  • 12.2.8 Key Customer Criteria
• 12.3 Product Life Cycle
• 12.4 Segmentation By Service
  • 12.4.1 Screening
  • 12.4.2 Diagnostic
  • 12.4.3 Interventional
• 12.5 Segmentation By Imaging Modality
  • 12.5.1 D Digital
  • 12.5.2 D Digital Breast Tomosynthesis
  • 12.5.3 Contrast-enhanced
  • 12.5.4 Other Imaging Modality
• 12.6 Segmentation By End-User
  • 12.6.1 Hospitals
  • 12.6.2 Specialty Clinics
  • 12.6.3 Diagnostic Centers
  • 12.6.4 Other End-User
• 12.7 Segmentation By Country
  • 12.7.1 China
    • 12.7.1.1 Segmentation By Service
      • 12.7.1.1.1 Screening
      • 12.7.1.1.2 Diagnostic
      • 12.7.1.1.3 Interventional
    • 12.7.1.2 Segmentation By Imaging Modality
      • 12.7.1.2.1 D Digital
      • 12.7.1.2.2 D Digital Breast Tomosynthesis
      • 12.7.1.2.3 Contrast-Enhanced
      • 12.7.1.2.4 Other Imaging Modality
    • 12.7.1.3 Segmentation By End-User
      • 12.7.1.3.1 Hospitals
      • 12.7.1.3.2 Specialty Clinics
      • 12.7.1.3.3 Diagnostic Centers
      • 12.7.1.3.4 Other End-User
  • 12.7.2 Japan
    • 12.7.2.1 Segmentation By Service
      • 12.7.2.1.1 Screening
      • 12.7.2.1.2 Diagnostic
      • 12.7.2.1.3 Interventional
    • 12.7.2.2 Segmentation By Imaging Modality
      • 12.7.2.2.1 D Digital
      • 12.7.2.2.2 D Digital Breast Tomosynthesis
      • 12.7.2.2.3 Contrast-Enhanced
      • 12.7.2.2.4 Other Imaging Modality
    • 12.7.2.3 Segmentation By End-User
      • 12.7.2.3.1 Hospitals
      • 12.7.2.3.2 Specialty Clinics
      • 12.7.2.3.3 Diagnostic Centers
      • 12.7.2.3.4 Other End-User
  • 12.7.3 India
    • 12.7.3.1 Segmentation By Service
      • 12.7.3.1.1 Screening
      • 12.7.3.1.2 Diagnostic
      • 12.7.3.1.3 Interventional
    • 12.7.3.2 Segmentation By Imaging Modality
      • 12.7.3.2.1 D Digital
      • 12.7.3.2.2 D Digital Breast Tomosynthesis
      • 12.7.3.2.3 Contrast-Enhanced
      • 12.7.3.2.4 Other Imaging Modality
    • 12.7.3.3 Segmentation By End-User
      • 12.7.3.3.1 Hospitals
      • 12.7.3.3.2 Specialty Clinics
      • 12.7.3.3.3 Diagnostic Centers
      • 12.7.3.3.4 Other End-User
  • 12.7.4 South Korea
    • 12.7.4.1 Segmentation By Service
      • 12.7.4.1.1 Screening
      • 12.7.4.1.2 Diagnostic
      • 12.7.4.1.3 Interventional
    • 12.7.4.2 Segmentation By Imaging Modality
      • 12.7.4.2.1 D Digital
      • 12.7.4.2.2 D Digital Breast Tomosynthesis
      • 12.7.4.2.3 Contrast-Enhanced
      • 12.7.4.2.4 Other Imaging Modality
    • 12.7.4.3 Segmentation By End-User
      • 12.7.4.3.1 Hospitals
      • 12.7.4.3.2 Specialty Clinics
      • 12.7.4.3.3 Diagnostic Centers
      • 12.7.4.3.4 Other End-User
  • 12.7.5 Australia
    • 12.7.5.1 Segmentation By Service
      • 12.7.5.1.1 Screening
      • 12.7.5.1.2 Diagnostic
      • 12.7.5.1.3 Interventional
    • 12.7.5.2 Segmentation By Imaging Modality
      • 12.7.5.2.1 D Digital
      • 12.7.5.2.2 D Digital Breast Tomosynthesis
      • 12.7.5.2.3 Contrast-Enhanced
      • 12.7.5.2.4 Other Imaging Modality
    • 12.7.5.3 Segmentation By End-User
      • 12.7.5.3.1 Hospitals
      • 12.7.5.3.2 Specialty Clinics
      • 12.7.5.3.3 Diagnostic Centers
      • 12.7.5.3.4 Other End-User
  • 12.7.6 Malaysia
    • 12.7.6.1 Segmentation By Service
      • 12.7.6.1.1 Screening
      • 12.7.6.1.2 Diagnostic
      • 12.7.6.1.3 Interventional
    • 12.7.6.2 Segmentation By Imaging Modality
      • 12.7.6.2.1 D Digital
      • 12.7.6.2.2 D Digital Breast Tomosynthesis
      • 12.7.6.2.3 Contrast-Enhanced
      • 12.7.6.2.4 Other Imaging Modality
    • 12.7.6.3 Segmentation By End-User
      • 12.7.6.3.1 Hospitals
      • 12.7.6.3.2 Specialty Clinics
      • 12.7.6.3.3 Diagnostic Centers
      • 12.7.6.3.4 Other End-User
  • 12.7.7 Rest of Asia Pacific
    • 12.7.7.1 Segmentation By Service
      • 12.7.7.1.1 Screening
      • 12.7.7.1.2 Diagnostic
      • 12.7.7.1.3 Interventional
    • 12.7.7.2 Segmentation By Imaging Modality
      • 12.7.7.2.1 D Digital
      • 12.7.7.2.2 D Digital Breast Tomosynthesis
      • 12.7.7.2.3 Contrast-Enhanced
      • 12.7.7.2.4 Other Imaging Modality
    • 12.7.7.3 Segmentation By End-User
      • 12.7.7.3.1 Hospitals
      • 12.7.7.3.2 Specialty Clinics
      • 12.7.7.3.3 Diagnostic Centers
      • 12.7.7.3.4 Other End-User

Chapter 13. LAMEA Market

• 13.1 Market Overview
• 13.2 Key Factors Impacting Market
  • 13.2.1 Market Drivers
  • 13.2.2 Market Restraints
  • 13.2.3 Market Opportunities
  • 13.2.4 Market Challenges
  • 13.2.5 Market Trends
  • 13.2.6 State of Competition
  • 13.2.7 Market Consolidation
  • 13.2.8 Key Customer Criteria
• 13.3 Product Life Cycle
• 13.4 Segmentation By Service
  • 13.4.1 Screening
  • 13.4.2 Diagnostic
  • 13.4.3 Interventional
• 13.5 Segmentation By Imaging Modality
  • 13.5.1 D Digital
  • 13.5.2 D Digital Breast Tomosynthesis
  • 13.5.3 Contrast-Enhanced
  • 13.5.4 Other Imaging Modality
• 13.6 Segmentation By End-User
  • 13.6.1 Hospitals
  • 13.6.2 Specialty Clinics
  • 13.6.3 Diagnostic Centers
  • 13.6.4 Other End-User
• 13.7 Segmentation By Country
  • 13.7.1 Brazil
    • 13.7.1.1 Segmentation By Service
      • 13.7.1.1.1 Screening
      • 13.7.1.1.2 Diagnostic
      • 13.7.1.1.3 Interventional
    • 13.7.1.2 Segmentation By Imaging Modality
      • 13.7.1.2.1 D Digital
      • 13.7.1.2.2 D Digital Breast Tomosynthesis
      • 13.7.1.2.3 Contrast-Enhanced
      • 13.7.1.2.4 Other Imaging Modality
    • 13.7.1.3 Segmentation By End-User
      • 13.7.1.3.1 Hospitals
      • 13.7.1.3.2 Specialty Clinics
      • 13.7.1.3.3 Diagnostic Centers
      • 13.7.1.3.4 Other End-User
  • 13.7.2 Argentina
    • 13.7.2.1 Segmentation By Service
      • 13.7.2.1.1 Screening
      • 13.7.2.1.2 Diagnostic
      • 13.7.2.1.3 Interventional
    • 13.7.2.2 Segmentation By Imaging Modality
      • 13.7.2.2.1 D Digital
      • 13.7.2.2.2 D Digital Breast Tomosynthesis
      • 13.7.2.2.3 Contrast-Enhanced
      • 13.7.2.2.4 Other Imaging Modality
    • 13.7.2.3 Segmentation By End-User
      • 13.7.2.3.1 Hospitals
      • 13.7.2.3.2 Specialty Clinics
      • 13.7.2.3.3 Diagnostic Centers
      • 13.7.2.3.4 Other End-User
  • 13.7.3 UAE
    • 13.7.3.1 Segmentation By Service
      • 13.7.3.1.1 Screening
      • 13.7.3.1.2 Diagnostic
      • 13.7.3.1.3 Interventional
    • 13.7.3.2 Segmentation By Imaging Modality
      • 13.7.3.2.1 D Digital
      • 13.7.3.2.2 D Digital Breast Tomosynthesis
      • 13.7.3.2.3 Contrast-Enhanced
      • 13.7.3.2.4 Other Imaging Modality
    • 13.7.3.3 Segmentation By End-User
      • 13.7.3.3.1 Hospitals
      • 13.7.3.3.2 Specialty Clinics
      • 13.7.3.3.3 Diagnostic Centers
      • 13.7.3.3.4 Other End-User
  • 13.7.4 Saudi Arabia
    • 13.7.4.1 Segmentation By Service
      • 13.7.4.1.1 Screening
      • 13.7.4.1.2 Diagnostic
      • 13.7.4.1.3 Interventional
    • 13.7.4.2 Segmentation By Imaging Modality
      • 13.7.4.2.1 D Digital
      • 13.7.4.2.2 D Digital Breast Tomosynthesis
      • 13.7.4.2.3 Contrast-Enhanced
      • 13.7.4.2.4 Other Imaging Modality
    • 13.7.4.3 Segmentation By End-User
      • 13.7.4.3.1 Hospitals
      • 13.7.4.3.2 Specialty Clinics
      • 13.7.4.3.3 Diagnostic Centers
      • 13.7.4.3.4 Other End-User
  • 13.7.5 South Africa
    • 13.7.5.1 Segmentation By Service
      • 13.7.5.1.1 Screening
      • 13.7.5.1.2 Diagnostic
      • 13.7.5.1.3 Interventional
    • 13.7.5.2 Segmentation By Imaging Modality
      • 13.7.5.2.1 D Digital
      • 13.7.5.2.2 D Digital Breast Tomosynthesis
      • 13.7.5.2.3 Contrast-Enhanced
      • 13.7.5.2.4 Other Imaging Modality
    • 13.7.5.3 Segmentation By End-User
      • 13.7.5.3.1 Hospitals
      • 13.7.5.3.2 Specialty Clinics
      • 13.7.5.3.3 Diagnostic Centers
      • 13.7.5.3.4 Other End-User
  • 13.7.6 Nigeria
    • 13.7.6.1 Segmentation By Service
      • 13.7.6.1.1 Screening
      • 13.7.6.1.2 Diagnostic
      • 13.7.6.1.3 Interventional
    • 13.7.6.2 Segmentation By Imaging Modality
      • 13.7.6.2.1 D Digital
      • 13.7.6.2.2 D Digital Breast Tomosynthesis
      • 13.7.6.2.3 Contrast-Enhanced
      • 13.7.6.2.4 Other Imaging Modality
    • 13.7.6.3 Segmentation By End-User
      • 13.7.6.3.1 Hospitals
      • 13.7.6.3.2 Specialty Clinics
      • 13.7.6.3.3 Diagnostic Centers
      • 13.7.6.3.4 Other End-User
  • 13.7.7 Rest of LAMEA
    • 13.7.7.1 Segmentation By Service
      • 13.7.7.1.1 Screening
      • 13.7.7.1.2 Diagnostic
      • 13.7.7.1.3 Interventional
    • 13.7.7.2 Segmentation By Imaging Modality
      • 13.7.7.2.1 D Digital
      • 13.7.7.2.2 D Digital Breast Tomosynthesis
      • 13.7.7.2.3 Contrast-Enhanced
      • 13.7.7.2.4 Other Imaging Modality
    • 13.7.7.3 Segmentation By End-User
      • 13.7.7.3.1 Hospitals
      • 13.7.7.3.2 Specialty Clinics
      • 13.7.7.3.3 Diagnostic Centers
      • 13.7.7.3.4 Other End-User

Chapter 14. Company Snapshots

• 14.1 Hologic, Inc.
  • 14.1.1 Business Overview
  • 14.1.2 Key Information
  • 14.1.3 Company Focus on Mammography Market
  • 14.1.4 Strategic Insights
  • 14.1.5 Strategy Deployed
  • 14.1.6 Product & Service Portfolio
  • 14.1.7 Capability Overview
  • 14.1.8 Core Competencies
  • 14.1.9 Technology & Innovation Focus
  • 14.1.10 SWOT Analysis
  • 14.1.11 Customers / End Users
  • 14.1.12 Competitive Positioning
  • 14.1.13 Key Differentiators
  • 14.1.14 Mammography Portfolio Matrix
  • 14.1.15 Analyst View
  • 14.1.16 Future Outlook
• 14.2 GE HealthCare Technologies Inc.
  • 14.2.1 Business Overview
  • 14.2.2 Key Information
  • 14.2.3 Company Focus on Mammography Market
  • 14.2.4 Strategic Insights
  • 14.2.5 Strategy Deployed
  • 14.2.6 Product & Service Portfolio
  • 14.2.7 Capability Overview
  • 14.2.8 Technology & Innovation Focus
  • 14.2.9 SWOT Analysis
  • 14.2.10 Customers / End Users
  • 14.2.11 Competitive Positioning
  • 14.2.12 Key Differentiators
  • 14.2.13 Mammography Portfolio Matrix
  • 14.2.14 Analyst View
  • 14.2.15 Future Outlook
• 14.3 Siemens Healthineers AG
  • 14.3.1 Business Overview
  • 14.3.2 Key Information
  • 14.3.3 Company Focus on Mammography Market
  • 14.3.4 Strategic Insights
  • 14.3.5 Strategy Deployed
  • 14.3.6 Product & Service Portfolio
  • 14.3.7 Capability Overview
  • 14.3.8 Core Competencies
  • 14.3.9 Technology & Innovation Focus
  • 14.3.10 SWOT Analysis
  • 14.3.11 Customers / End Users
  • 14.3.12 Competitive Positioning
  • 14.3.13 Key Differentiators
  • 14.3.14 Mammography Portfolio Matrix
  • 14.3.15 Analyst View
  • 14.3.16 Future Outlook
• 14.4 FUJIFILM Holdings Corporation
  • 14.4.1 Business Overview
  • 14.4.2 Key Information
  • 14.4.3 Company Focus on Mammography Market
  • 14.4.4 Strategic Insights
  • 14.4.5 Strategy Deployed
  • 14.4.6 Product & Service Portfolio
  • 14.4.7 Capability Overview
  • 14.4.8 Core Competencies
  • 14.4.9 Technology & Innovation Focus
  • 14.4.10 SWOT Analysis
  • 14.4.11 Customers / End Users
  • 14.4.12 Competitive Positioning
  • 14.4.13 Key Differentiators
  • 14.4.14 Mammography Portfolio Matrix
  • 14.4.15 Analyst View
  • 14.4.16 Future Outlook
• 14.5 Planmed Oy
  • 14.5.1 Business Overview
  • 14.5.2 Key Information
  • 14.5.3 Company Focus on Mammography Market
  • 14.5.4 Strategic Insights
  • 14.5.5 Strategy Deployed
  • 14.5.6 Product & Service Portfolio
  • 14.5.7 Capability Overview
  • 14.5.8 Core Competencies
  • 14.5.9 Technology & Innovation Focus
  • 14.5.10 SWOT Analysis
  • 14.5.11 Customers / End Users
  • 14.5.12 Competitive Positioning
  • 14.5.13 Key Differentiators
  • 14.5.14 Mammography Portfolio Matrix
  • 14.5.15 Analyst View
  • 14.5.16 Future Outlook
• 14.6 IMS Giotto S.p.A.
  • 14.6.1 Business Overview
  • 14.6.2 Key Information
  • 14.6.3 Company Focus on Mammography Market
  • 14.6.4 Strategic Insights
  • 14.6.5 Strategy Deployed
  • 14.6.6 Product & Service Portfolio
  • 14.6.7 Capability Overview
  • 14.6.8 Technology & Innovation Focus
  • 14.6.9 SWOT Analysis
  • 14.6.10 Customers / End Users
  • 14.6.11 Competitive Positioning
  • 14.6.12 Key Differentiators
  • 14.6.13 Portfolio Matrix
  • 14.6.14 Analyst View
  • 14.6.15 Future Outlook
• 14.7 Metaltronica S.p.A.
  • 14.7.1 Business Overview
  • 14.7.2 Key Information
  • 14.7.3 Company Focus on Mammography Market
  • 14.7.4 Strategic Insights on Mammography Market
  • 14.7.5 Strategy Deployed
  • 14.7.6 Product & Service Portfolio
  • 14.7.7 Capability Overview
  • 14.7.8 Technology & Innovation Focus
  • 14.7.9 SWOT Analysis
  • 14.7.10 Customers / End Users
  • 14.7.11 Competitive Positioning
  • 14.7.12 Key Differentiators
  • 14.7.13 Portfolio Matrix
  • 14.7.14 Analyst View
  • 14.7.15 Future Outlook
• 14.8 Trivitron Healthcare Pvt. Ltd.
  • 14.8.1 Business Overview
  • 14.8.2 Key Information
  • 14.8.3 Company Focus on Mammography Market
  • 14.8.4 Strategic Insights
  • 14.8.5 Strategy Deployed
  • 14.8.6 Product & Service Portfolio
  • 14.8.7 Capability Overview
  • 14.8.8 Technology & Innovation Focus
  • 14.8.9 SWOT Analysis
  • 14.8.10 Customers / End Users
  • 14.8.11 Competitive Positioning
  • 14.8.12 Key Differentiators
  • 14.8.13 Portfolio Matrix
  • 14.8.14 Analyst View
  • 14.8.15 Future Outlook
• 14.9 Allengers Medical Systems Ltd.
  • 14.9.1 Business Overview
  • 14.9.2 Key Information
  • 14.9.3 Company Focus on Mammography Market
  • 14.9.4 Strategic Insights
  • 14.9.5 Strategy Deployed
  • 14.9.6 Product & Service Portfolio
  • 14.9.7 Capability Overview
  • 14.9.8 Technology & Innovation Focus
  • 14.9.9 SWOT Analysis
  • 14.9.10 Customers / End Users
  • 14.9.11 Competitive Positioning
  • 14.9.12 Key Differentiators
  • 14.9.13 Portfolio Matrix
  • 14.9.14 Analyst View
  • 14.9.15 Future Outlook
• 14.10 MEDI-FUTURE Co., Ltd.
  • 14.10.1 Business Overview
  • 14.10.2 Key Information
  • 14.10.3 Company Focus on Mammography Market
  • 14.10.4 Strategic Insights
  • 14.10.5 Strategy Deployed
  • 14.10.6 Product & Service Portfolio
  • 14.10.7 Capability Overview
  • 14.10.8 Technology & Innovation Focus
  • 14.10.9 SWOT Analysis
  • 14.10.10 Customers / End Users
  • 14.10.11 Competitive Positioning
  • 14.10.12 Key Differentiators
  • 14.10.13 Portfolio Matrix
  • 14.10.14 Analyst View
  • 14.10.15 Future Outlook

Chapter 15. Winning Imperatives